Newsfeeds - Spark Newswire

3 minute read

Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge

Today, 7:05 AM

Toward the end of trading Thursday, the Dow traded down 0.20% to 34,745 while the NASDAQ fell 0.03% to 15,157.61. The S&P also fell, dropping 0.21% to 4,471.34.

AERI

2 minute read

MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation

By Vandana Singh

Today, 7:05 AM

MacroGenics Inc (NASDAQ: MGNX)

MGNX

2 minute read

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 7:05 AM

AERI

4 minute read

38 Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

Today, 7:05 AM

Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the stock on social media.

AERI

3 minute read

Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August

By Lisa Levin

Today, 7:05 AM

Following the market opening Thursday, the Dow traded down 0.45% to 34,657.69 while the NASDAQ fell 0.66% to 15,061.97. The S&P also fell, dropping 0.62% to 4,453.04.

AERI

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 7:05 AM

ACER

4 minute read

The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs

By Shanthi Rexaline

Today, 7:05 AM

Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week.

ALRN

5 minute read

The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod

By Shanthi Rexaline

Today, 7:05 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7)

ADIL

1 minute read

MacroGenics’ Cancer Drug Margenza Flops On Overall Survival Analysis

By Vandana Singh

Today, 7:05 AM

MacroGenics Inc (NASDAQ:MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a…

MGNX

6 minute read

MacroGenics Announces Final Overall Survival Results From SOPHIA Study Of MARGENZA In Patients With HER2-Positive Metastatic Breast Cancer Did Not Demonstrate Statistically Significant Advantage For MARGENZA Over Trastuzumab

By Bill Haddad

Today, 7:05 AM

Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying

MGNX